Skip to main content
SpringerLink
Log in

Targeted Treatment of Gallbladder Cancer

  • Chapter
  • First Online:
Gallbladder Cancer

  • 378 Accesses

Abstract

Gallbladder cancer is the common malignancy in north Indian states, especially Bihar and Uttar Pradesh. Rarity of gallbladder cancer in the western world precluded it from active research for the last two decades. Gemcitabine- and platinum-based combination therapy remained the treatment of choice over these years. Delayed presentations and aggressive biology made this disease largely incurable in early disease state and goal remains palliative in advanced or metastatic disease. Targeted therapies in the form Tyrosine kinase inhibitors, monoclonal antibodies against specific cancer cell receptor and immunotherapy has improved outcomes in various cancers. Recent approval of FGFR2 inhibitors and IDH1 inhibitors in metastatic cholangiocarcinoma is an early sign of potential of targeted therapy in biliary tract cancers which is enriched in targetable molecular pathways in two-third of the cases. We reviewed the literature and highlighted the emerging new and effective treatment strategies for this otherwise aggressive and fatal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Herceptin has saved countless women’s lives and earned UCLA’s Dr. Dennis Slamon the Lasker Award—Physicians Update—UCLA Health—Los Angeles, CA [Internet]]. https://www.uclahealth.org/physiciansupdate/herceptin-has-saved-countless-women-s-lives-and-earned-ucla-s-dr-dennis-slamon-the-lasker-award. Accessed 27 Mar 2021.

  2. Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–44.

    Article  CAS  Google Scholar 

  3. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;(August):1–11.

    Google Scholar 

  4. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–10.

    Article  CAS  Google Scholar 

  5. Jeffrey S. Ross KW, Albany Medical College A, Foundation Medicine I, The University of Chicago C, Foundation Medicine Inc. C, The University of Texas MD Anderson Cancer Center H. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. https://meetinglibrary.asco.org/record/105256/abstract. Accessed 11 Jun 2021.

  6. Mondaca S, Razavi P, Xu C, Offin M, Myers M, Scaltriti M, et al. Genomic characterization of ERBB2-driven biliary cancer and a case of response to ado-Trastuzumab Emtansine. JCO Precis Oncol. 2019;3:1–9.

    Google Scholar 

  7. Patel A, Singh HP, Pandalanghat S, Kumar M, Guleria B, Mathighatta Shivarudraiah SS. Genomic architecture of gallbladder cancer: results of a first prospective study. J Clin Oncol. 2020;38(15_suppl):e16628.

    Article  Google Scholar 

  8. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.

    Article  CAS  Google Scholar 

  9. Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun. 2021;27:100354.

    Article  Google Scholar 

  10. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631.

    Article  CAS  Google Scholar 

  11. Malka D, Cervera P, Foulon S, Trarbach T, de Fouchardière C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–28.

    Article  CAS  Google Scholar 

  12. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006;12(6):1680–5.

    Article  CAS  Google Scholar 

  13. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–74.

    Article  CAS  Google Scholar 

  14. Lee J, Park SH, Chang H-M, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8.

    Article  CAS  Google Scholar 

  15. Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus Gefitinib plus Pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38(2):124–36.

    Article  CAS  Google Scholar 

  16. Soni K, Kumar T, Pandey M. Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature. World J Surg Oncol [Internet]. 2020;18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335444/. Accessed 31 May 2021.

  17. Patel A, Singh HP, Pandalanghat S, Kumar M, Guleria B, MathighattaShivarudraiah SS. Genomic architecture of gallbladder cancer: results of a first prospective study. J Clin Oncol. 2020;38(15_suppl):e16628.

    Article  Google Scholar 

  18. Pereira P, Oliveira I, Fernandes S, Clara A, Miguel I, Bento S, et al. Biliary tract cancers in Portuguese families with BRCA gene mutation: a retrospective study. Ann Oncol. 2019;30:v281.

    Article  Google Scholar 

  19. Xie Y, Jiang Y, Yang X-B, Wang A-Q, Zheng Y-C, Wan X-S, et al. Response of BRCA1-mutated gallbladder cancer to olaparib: a case report. World J Gastroenterol. 2016;22(46):10254–9.

    Article  Google Scholar 

  20. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34(1):157–64.

    Article  CAS  Google Scholar 

  21. Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res. 2014;7(2):42–8.

    Google Scholar 

  22. Nam A-R, Kim J-W, Cha Y, Ha H, Park JE, Bang J-H, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 2016;7(36):58007–21.

    Article  Google Scholar 

  23. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8(1):58. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469402/.

    Article  Google Scholar 

  24. Patel A, Soneji D, Singh HP, Kumar M, Bandyopadhyay A, Mathur A, et al. Genomic landscape and targeted treatment of gallbladder cancer: results of a first ongoing prospective study. South Asian J Cancer. 2020;9(2):74–9.

    Article  Google Scholar 

  25. Das CK, Patel A, Raj A, Gupta VG, Mehta P, Bhethanabhotla S, et al. Anti-Her2neu directed therapy in advanced gall bladder cancer: a prospective, multicenter experience from India. J Clin Oncol. 2020;38(15_suppl):e16682.

    Article  Google Scholar 

  26. CTRI [Internet]. http://ctri.nic.in/Clinicaltrials/regtrial.php?modid=1&compid=19&EncHid=78443.24609. Accessed 27 Mar 2021.

  27. Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol. 2014;27(7):1028–34.

    Article  CAS  Google Scholar 

  28. Saetta AA, Papanastasiou P, Michalopoulos NV, Gigelou F, Korkolopoulou P, Bei T, et al. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch Int J Pathol. 2004;445(2):179–82.

    Article  CAS  Google Scholar 

  29. Li W, Cui Y, Yin F, Peng L, Liu X, Shen Y, et al. BRAF mutation in Chinese biliary tract cancer patients. J Clin Oncol. 2020;38(15_suppl):e16678.

    Article  Google Scholar 

  30. Sholl LM. A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications. Precis Cancer Med. 2020;3:26.

    Article  Google Scholar 

  31. Zaman A, Wu W, Bivona TG. Targeting oncogenic BRAF: past, present, and future [internet]. Cancer. 2019;11:1197. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721448/.

    Article  CAS  Google Scholar 

  32. Lavingia V, Fakih M. Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma—2 case reports and a brief review. J Gastrointest Oncol. 2016;7(6). https://jgo.amegroups.com/article/view/10405.

  33. Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, et al. Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol. 2020;38(33):3895–904.

    Article  CAS  Google Scholar 

  34. Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–43.

    Article  CAS  Google Scholar 

  35. Research C for DE and. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. FDA [Internet]. 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion. Accessed 30 Apr 2020.

  36. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30109-1/abstract. Accessed 30 Apr 2020.

  37. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010;11(1):48–54.

    Google Scholar 

  38. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clin Oncol. 2010;28(21):3491–7.

    Article  CAS  Google Scholar 

  39. Zhang M, Zhang P, Zhou K, Li Q. Remarkable response of metastatic gallbladder carcinoma to Apatinib after failed multiline chemotherapies: a case report and literature review. Front Oncol. 2019;9:1180. https://doi.org/10.3389/fonc.2019.01180/full.

    Article  Google Scholar 

  40. Mou H, Xie Q, Yu LF, Liao Q, Yang Y, Wu Y. Efficacy and safety of apatinib in refractory unresectable and metastatic cholangiocarcinoma: a retrospective analysis. J Clin Oncol. 2018;36(15_suppl):e16123.

    Article  Google Scholar 

  41. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513(7516):110–4.

    Article  CAS  Google Scholar 

  42. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807.

    Article  CAS  Google Scholar 

  43. Demols A, Rocq L, Charry M, De Nève N, Verrellen A, Ramadhan A, et al. NTRK gene fusions in biliary tract cancers. J Clin Oncol. 2020;38(4_suppl):574.

    Article  Google Scholar 

  44. Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38–46.

    Article  CAS  Google Scholar 

  45. Rizzo A, Ricci AD, Brandi G. Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives. Expert Rev Precis Med Drug Dev. 2021;6:225–7.

    Article  Google Scholar 

  46. Lassen U. How I treat NTRK gene fusion-positive cancers. ESMO Open. 2019;4(Suppl 2):e000612.

    Article  Google Scholar 

  47. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82.

    Article  CAS  Google Scholar 

  48. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9.

    Article  CAS  Google Scholar 

  49. Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, et al. Evaluation of combination Nivolumab and Ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol. 2020;6(9):1405–9.

    Article  Google Scholar 

  50. Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, et al. A phase 2 multi-institutional study of Nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888–94.

    Article  Google Scholar 

  51. Alshari OM, Dawaymeh TA, Tashtush NA, Aleshawi AJ, Manasra ARAA, Obeidat KA. Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases. Onco Targets Ther. 2019;12:5293–8.

    Article  CAS  Google Scholar 

  52. Patel A, Soneji D, Parikh P, Kumar M. Biomarkers in immuno-oncology: a review article. Int J Mol Immuno. Oncologia. 2019;4(2):41–9.

    Google Scholar 

  53. Neyaz A, Husain N, Kumari S, Gupta S, Shukla S, Arshad S, et al. Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy. Histopathology. 2018;73(4):622–33.

    Article  Google Scholar 

  54. Boilève A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc J-F, et al. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: safety run-in results of the randomized IMMUNOBILPRODIGE 57 phase II trial. Eur J Cancer. 2021;143:55–63.

    Article  Google Scholar 

  55. Pandey A, Stawiski EW, Durinck S, Gowda H, Goldstein LD, Barbhuiya MA, et al. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. Nat Commun. 2020;11(1):4225.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Oncology Centre, INHS ASVINI, Mumbai, India

    Amol Patel

  2. INHS ASVINI, Mumbai, India

    Vivek Hande

Authors
  1. Amol Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivek Hande
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of General Surgery, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Vijay Kumar Shukla

  2. Department of Surgical Oncology, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Manoj Pandey

  3. Department of General Surgery, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Ruhi Dixit

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Patel, A., Hande, V. (2023). Targeted Treatment of Gallbladder Cancer. In: Kumar Shukla, V., Pandey, M., Dixit, R. (eds) Gallbladder Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-19-6442-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-6442-8_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-6441-1

  • Online ISBN: 978-981-19-6442-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation